TherapeuticsMD, Inc.
TXMDAnalyst Consensus
Rating Trend
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Cantor Fitzgerald | maintain | Neutral | Aug 17, 2023 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 7, 2022 |
| Cantor Fitzgerald | downgrade | Overweight →Neutral | May 6, 2022 |
| HC Wainwright & Co. | maintain | Buy | Mar 11, 2022 |
| HC Wainwright & Co. | maintain | Buy | Nov 12, 2021 |
| Jefferies | downgrade | Hold →Underperform | Aug 7, 2020 |
| JP Morgan | downgrade | Overweight →Neutral | May 19, 2020 |
| Stifel | maintain | Buy | Apr 16, 2020 |
| H.C. Wainwright | maintain | Buy | Feb 21, 2020 |
| Cantor Fitzgerald | maintain | Overweight | Aug 14, 2018 |
| Oppenheimer | upgrade | Perform →Outperform | Jul 11, 2017 |
| Oppenheimer | downgrade | Outperform →Perform | May 9, 2017 |
| Stifel Nicolaus | maintain | Buy | Dec 6, 2016 |
| Stifel Nicolaus | maintain | Buy | Mar 4, 2014 |
Earnings History
Next report: Nov 17, 2026 · EPS est. $-6.13| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 11, 2026 | $0.01 | $-6.13 | $869.0K | $19.8M |
| May 12, 2026 | $0.01 | $-6.13 | $724.0K | $19.8M |
| Mar 30, 2026 | $-0.05 | $0.04 | $893.0K | $2.3M |
| Nov 12, 2025 | $0.01 | — | $784.0K | — |
| Aug 12, 2025 | $0.05 | — | $952.0K | — |
| May 13, 2025 | $-0.06 | — | $393.0K | — |
| Mar 27, 2025 | $0.02 | $0.04 | $667.0K | $2.3M |
| Nov 12, 2024 | $-0.05 | $0.04 | $547.0K | $2.3M |
News
NRx Pharmaceuticals (NASDAQ: NRXP - Get Free Report) and TherapeuticsMD (NASDAQ: TXMD - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, valuation, earnings, risk and dividends. Institutional and Insider Ownership 4.3% of NRx Pharmaceuticals
TherapeuticsMD (NASDAQ: TXMD - Get Free Report) and Tilray Brands (NASDAQ: TLRY - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends. Volatility and Risk TherapeuticsMD has a beta of
TherapeuticsMD, Inc. (âTherapeuticsMDâ or the âCompanyâ) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financia
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com.